David MD - Intellia Therapeutics Executive Officer
| NTLA Stock | USD 13.80 0.68 5.18% |
Executive
David MD is Executive Officer of Intellia Therapeutics
| Age | 69 |
| Address | 40 Erie Street, Cambridge, MA, United States, 02139 |
| Phone | 857 285 6200 |
| Web | https://www.intelliatx.com |
Intellia Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2781) % which means that it has lost $0.2781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5223) %, meaning that it created substantial loss on money invested by shareholders. Intellia Therapeutics' management efficiency ratios could be used to measure how well Intellia Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.39. In addition to that, Return On Capital Employed is expected to decline to -0.46. At present, Intellia Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 317.8 M, whereas Total Assets are forecasted to decline to about 686.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Terry MD | Sana Biotechnology | 57 | |
| Linda Burkly | Editas Medicine | 67 | |
| Snehal Patel | Sana Biotechnology | N/A | |
| Susie Lisa | Vertex Pharmaceuticals | N/A | |
| Raju Prasad | Crispr Therapeutics AG | 40 | |
| MD FACP | Crispr Therapeutics AG | 50 | |
| Jonathan JD | Vertex Pharmaceuticals | 60 | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| Samarth Kulkarni | Crispr Therapeutics AG | 46 | |
| Karen Tepichin | Ginkgo Bioworks Holdings | N/A | |
| Bethany Cavanagh | Beam Therapeutics | N/A | |
| Troy Lister | Verve Therapeutics | N/A | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| Nina Devlin | Vertex Pharmaceuticals | N/A | |
| Timothy MBA | Caribou Biosciences | 55 | |
| Jennifer Robinson | Verve Therapeutics | N/A | |
| Daniel Anderson | Crispr Therapeutics AG | N/A | |
| Cindy Tahl | Fate Therapeutics | 51 | |
| Linea Aspesi | Editas Medicine | 54 | |
| Anna Wagner | Ginkgo Bioworks Holdings | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 |
Intellia Therapeutics Leadership Team
Elected by the shareholders, the Intellia Therapeutics' board of directors comprises two types of representatives: Intellia Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intellia. The board's role is to monitor Intellia Therapeutics' management team and ensure that shareholders' interests are well served. Intellia Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intellia Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Doudna, Founder Board | ||
| Rachel Haurwitz, CoFounder | ||
| Nessan Bermingham, President CEO, Founder, Director | ||
| Glenn CPA, CFO VP | ||
| Derek Hicks, Executive Officer | ||
| JD Esq, General VP | ||
| Rodolphe MBA, Founder Board | ||
| Andrew May, Founder Board | ||
| David MD, Executive Officer | ||
| Laura SeppLorenzino, Executive Vice President Chief Scientific Officer | ||
| John MD, CEO President | ||
| Derrick Rossi, Founder Board |
Intellia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intellia Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (15.89) % | ||||
| Current Valuation | 779.76 M | ||||
| Shares Outstanding | 101.85 M | ||||
| Shares Owned By Insiders | 1.20 % | ||||
| Shares Owned By Institutions | 91.28 % | ||||
| Number Of Shares Shorted | 16.15 M | ||||
| Price To Earning | (19.91) X | ||||
| Price To Book | 1.39 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.